Disagree
Home Euro-Pharmacies Euro-Pharmacies
Cialix 20 BLISTER
Cialix 20 BLISTER - Euro-Pharmacies

Cialix 20 BLISTER - Euro-Pharmacies

Brand:
Category:
Substance:
Dosage:
20 mg/tab
Package:
20 tablets
Price:
$29.00 - $32.00
See options
Product Overview

Offering an extensive activity window, tadalafil, under the brand Cialis, transformed the ED treatment landscape. Recognized for its ability to support up to 36 hours of activity, tadalafil allows users to manage erectile dysfunction with a greater degree of flexibility. As a PDE5 inhibitor, tadalafil's mechanism supports blood flow through muscle relaxation during arousal, enabling smoother, more consistent results. Approved by the FDA in 2003, it quickly became popular for both daily and occasional use, appreciated for its dependable, versatile impact in men’s sexual health.

References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Cialix 20 BLISTER by Euro-Pharmacies, consult with your doctor or healthcare professional.

Products
Show more
Explore More Products
FAQ
What advantages does Cialis offer in terms of patient satisfaction?
Its extended action allows users more flexibility, enhancing satisfaction by supporting natural spontaneity.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Why did Cialis mark a milestone in ED treatment?
It provided an extended option that reduced the need to plan around dosing, marking a shift towards more convenient ED management.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

How did the discovery of sildenafil affect Cialis’s development?
Sildenafil’s unexpected effects on ED heightened interest in PDE5 inhibitors, encouraging further Cialis research.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.